Home › Agenus Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation
 

Keywords :   


Agenus Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation

2014-07-02 10:39:34| drugdiscoveryonline Home Page

Agenus Inc. an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, recently announced promising Phase 2 results for HerpV, a synthetic vaccine candidate for the treatment of patients with genital Herpes Simplex Virus-2 (HSV-2)

Tags: shows significant generated reduction

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05M&S website and app hit by technical issue
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Producers to be paid grid premiums for AngusLink beef scores
More »